dimyristoylphosphatidylinositol: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 131979 |
MeSH ID | M0210701 |
Synonym |
---|
dmpi |
[3-[hydroxy-[(2s,3r,5s,6s)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate |
1-(2,3-bis((1-oxotetradecyl)oxy)propyl hydrogen phosphate) myo-inositol |
136655-51-1 |
myo-inositol, 1-(2,3-bis((1-oxotetradecyl)oxy)propyl hydrogen phosphate) |
dimyristoylphosphatidylinositol |
3-({hydroxy[(2,3,4,5,6-pentahydroxycyclohexyl)oxy]phosphoryl}oxy)propane-1,2-diyl ditetradecanoate |
DTXSID20929507 |
Excerpt | Reference | Relevance |
---|---|---|
"Dimyristoylphosphatidylinositol (DMPI) has been synthesized with the appropriate natural stereochemistry and labelled with deuterium at specific sites in the D-myo-inositol headgroup. " | ( The conformational behaviour of phosphatidylinositol in model membranes: 2H-NMR studies. Boden, N; Bushby, RJ; Byard, SJ; Hansbro, PM; Novelli, R; Reid, DG; Saunders, MR; Turnbull, PJ, 1992) | 1.73 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |